Virus-based therapies for colon cancer

Expert Opinion on Biological Therapy

Volumn 5, Issue 12, 2005, Pages 1627-1633

  Morse, Michael A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenovirus; Colon cancer; HSV; Oncolysis; Vaccinia

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOVIRUS VECTOR; B7 ANTIGEN; CARBOXYLESTERASE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; HEAT SHOCK PROTEIN; HERPESVIRUS VECTOR; IRINOTECAN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; SURVIVIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CELL DESTRUCTION; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DRUG SAFETY; FATIGUE; FEVER; HERPES SIMPLEX VIRUS; HUMAN; INJECTION SITE REACTION; NONHUMAN; PROTEIN ENGINEERING; REVIEW; SUICIDE GENE THERAPY; SURGICAL WOUND; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COLONIC NEOPLASMS; GENE THERAPY; GENETIC VECTORS; HUMANS; ONCOLYTIC VIROTHERAPY;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; HERPESVIRIDAE; NEWCASTLE DISEASE VIRUS; REOVIRUS SP.; SIMPLEXVIRUS;

EID: 28844433692     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.12.1627     Document Type: Review

References (33)

1. KURUPPU D, TANABE KK: Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol. Ther. (2005) 4:524-531. Comprehensive review of viral oncolysis with details on important considerations for development of this therapy.
2. REID TR, GALANIS E, ABBRUZZESE J et al.: Intra-arterial administration of a replication-selective adenovirus Ci-1042 (Onyx-015) in patients with colorectal carcinoma metastatic to the liver: safety, feasibility and biological activity (abstract). Proc. Am. Soc. Clin. Oncol. (2001) 20:549a.
3. RODRIGUEZ R, SCHUUR ER, LIM HY, HENDERSON GA, SIMONS JW, HENDERSON DR: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. (1997) 57:2559-2563.
4. KOOBY DA, CAREW JF, HALTERMAN MW et al.: Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J. (1999) 13(11):1325-1334.
5. REINBLATT M, PIN RH, FEDEROFF HJ, FONG Y: Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases. Ann. Surg. (2004) 239(6):892-899; discussion 899-902.
6. CINATL J JR, MICHAELIS M, DRIEVER PH et al.: Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia (2004) 6(6):725-735.
7. NAKANO K, TODO T, ZHAO G et al.: Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. J. Gene Med. (2005) 7(5):638-648.
8. BENNETT JJ, DELMAN KA, BURT BM et al.: Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther. (2002) 9(11):935-945.
9. FONG Y, JARNAGIN W, GUILFOYLE B et al.: Results of a Phase I, dose-escalating study of the safety, tolerability, and anti-tumor activity of a single injection of a genetically engineered herpes simplex virus, NV1020, in subjects with hepatic colorectal metastases. Proc. Am. Soc. Clin. Oncol. (2005):abstract 242.
10. LORENCE RM, ROBERTS MS, GROENE WS et al.: Regression of human tumor xenografts following intravenous treatment using PV701, a naturally attenuated oncolytic strain of Newcastle disease virus. Proc. Am. Assoc. Cancer Res. (2001)42:2442a.
11. PECORA AL, RIZVI N, COHEN GI: An intravenous Phase I trial of a replication-competent virus, PV701, in the treatment of patients with advanced solid cancers. Proc. Am. Soc. Clin. Oncol. (2001) 20:1009a.
12. ZAGER JS, DELMAN KA, MALHOTRA S et al.: Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol. Med. (2001) 7:561-568.
13. COFFIN RS, HU JC, DAVIS CJ et al.: Results of a Phase I/II clinical trial with OncoVEXGM-CSF, a second generation oncolytic herpes simplex virus. Proc. Am. Soc. Clin. Oncol. (2005):abstract 3099.
14. MULLEN JT, DONAHUE JM, CHANDRASEKHAR S et al.: Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer (2004) 101:869-877.
15. WONG RJ, CHAN MK, YU Z et al.: Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin. Cancer Res. (2004) 10(13):4509-4516.
16. SOVA P, REN XW, NI S et al.: A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol. Ther. (2004) 9(4):496-509.
17. LI Y, CHEN Y, DILLEY J et al.: Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol. Cancer Ther. (2003) 2(10):1003-1009.
18. HIRASAWA K, NISHIKAWA SG, NORMAN KL, ALAIN T, KOSSAKOWSKA A, LEE PW: Oncolytic reovirus against ovarian and colon cancer. Cancer Res. (2002) 62(6):1696-1701.
19. TU SP, GUI JT, LISTON P et al.: Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology (2005) 128(2):361-375. Novel, adenovirally delivered, gene therapy-based approach for causing apoptosis of colon cancer.
20. AKBULUT H, TANG Y, MAYNARD J, ZHANG L, PIZZORNO G, DEISSEROTH A: Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms. Clin. Cancer Res. (2004) 10(22):7738-7746.
21. OOSTERHOFF D, OVERMEER RM, DE GRAAF M et al.: Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. Br. J. Cancer (2005) 92(5):882-887.
22. SLAVIN-CHIORINI DC, CATALFAMO M, KUDO-SAITO C, HODGE JW, SCHLOM J, SABZEVARI H: Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther. (2004) 11(10):665-680.
23. KASS E, SCHLOM J, THOMPSON J et al.: Induction of protective host immunity to carcinoembryonic antigen (CEA) a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. (1999) 59:676-683.
24. TSANG KY, ZAREMBA S, NIERODA CA et al.: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst. (1995) 87:982.
25. MARSHALL J, HAWKINS MJ, TSANG KY et al.: Phase I study in cancer patients of a replication-defective avipox recominbant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. (1999) 17:332-337. State-of-the-art clinical trial of a prime-boost poxvector-based vaccine for therapy of CEA-expressing malignancies, including colon cancer. This paper illustrates many of the challenges and opportunities of viral vector-based vaccines.
26. ZHU MZ, MARSHALL J, COLE D, SCHLOM J, TSANG KY: Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. (2000) 6:24-33.
27. VON MEHREN M, ARLEN P, TSANG KY et al.: Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. (2000) 6:2219-2228.
28. VON MEHREN M, DAVEY M, MCLAUGHLIN S et al.: Phase I Study of Vaccine Therapy with ALVAC-CEA B7.1 and GM-CSF (G) in Patients (PTS) with Advanced CEA-Expressing Cancers. Proc. Am. Soc. Clin. Oncol. (2000) 19:480a (abstract 1883).
29. VON MEHREN M et al.: The Influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. (2001) 7:1181-1191.
30. HORIG H, LEE DS, CONKRIGHT W et al.: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. (2000) 49:504-514.
31. MARSHALL J, HOYER RJ, TOOMEY MA et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. (2000) 18:3964-3974.
32. SLACK R, LEY L, CHANG P et al.: Association between CEA-specific T cell responses (TCR) following treatment with Vaccinia CEA (V) and Alvac CEA (A) and survival in patients with CEA bearing cancers. Proc. Am. Soc. Clin. Oncol. (2001) 20:272a (abstract 1086).
33. MARSHALL JL, GULLEY JL, ARLEN PM et al.: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. (2005) 23(4):720-731.